Our DNA

Best known for her impact on pharmacogenomics testing becoming a standard of care, Dr. Becky Winslow is a nationally recognized leader in in vitro diagnostics commercialization and clinical adoption strategy. As Founder and President of inGENEious RX, Inc., Dr. Winslow partners with diagnostic companies to accelerate innovative tests from concept to routine clinical practice.  

Previously, Dr. Winslow directed medication therapy management programs across retail, hospital, long-term care, and public health sectors for Walmart Inc., Community Health Systems, Inc., and the North Carolina Department of Health and Human Services. Her frustration with the limitations of traditional medication management tools fueled her passion for diagnostics that truly individualize patient care.

For over twelve years, she has guided diagnostic stakeholders in advancing molecular diagnostics and therapeutic strategies to improve patient outcomes. Dr. Winslow frequently presents at leading industry conferences such as the Association for Molecular Pathology and LabRoots educational platforms.

She holds a Bachelor of Science in Biology and a Doctor of Clinical Pharmacy degree from Campbell University and serves as a preceptor for Manchester University School of Pharmacy. Dr. Winslow’s work reflects a commitment to clinical innovation, healthcare transformation, and expanding patient access to high-value diagnostics. 

Dr. Mary Weissman is an inGENEious RX head consultant. Dr. Weissman completed a two-year pharmacogenomics fellowship with a clinical diagnostic lab after earning her PharmD from the Arnold and Marie Schwartz College of Pharmacy. Upon completing her academic training in pharmacology and pharmacogenomics, Dr. Weissman embarked on a journey to apply her expertise in clinical diagnostic laboratories. She has held several key scientific and clinical roles in pharmacogenomics laboratories. Through informative presentations, training sessions, papers, and webinars, she has helped clarify pharmacogenomics' complexities and highlight its potential to revolutionize medication management strategies for pharmacogenomics stakeholders.